GS Group, IMM Investment to jointly bid for Hugel Korean conglomerate emerging as frontrunner to acquire botox maker
Translated by Ryu Ho-joung 공개 2021-08-11 08:02:55
이 기사는 2021년 08월 11일 08:01 thebell 에 표출된 기사입니다.
South Korean conglomerate GS Group has teamed up with private equity firm IMM Investment to jointly bid for Bain Capital-owned botox maker Hugel, industry sources said on Monday.The US buyout firm and BoA-Merrill Lynch, which is managing the sale process, are in talks separately with potential buyers seeking to acquire a controlling stake in Hugel. Among them are a consortium of GS Group and IMM Investment, Chinese strategic investors and private equity firms, according to sources.
The GS consortium is viewed as the strongest candidate to win the race. In contrast with Shinsegae Group which withdrew from the deal last month, GS Group has opted to join forces with IMM Investment which will lead the consortium. This indicates the conglomerate’s strong interest in the pharmaceutical company, industry watchers said.
“The GS-IMM Investment consortium is emerging as the frontrunner to acquire Hugel,” an industry insider said. “It is unlikely that the seller will select a Chinese firm as the preferred buyer for several reasons.”
The South Korean pharmaceutical company is selling through a limited auction process. Another industry insider said, “Who will win the race remains to be seen because all bidders in the race have strong desire to acquire the company.”
The sale method was changed from a private sale to a limited auction as the stake sale attracted interest from many domestic and overseas investors. Bain reportedly intends to skip the preliminary round of bidding and receive binding offers from a select group of potential buyers.
Founded in 2001, Hugel is the country’s largest player in the market for botulinum toxin products by market share. The company went public on Kosdaq in 2015 and has since grown rapidly. Its consolidated revenue increased to a record of 211 billion won ($183.8 million) in 2020, compared to 182 billion won in 2017. Full-year 2021 revenue is projected to surpass 270 billion won.
Bain acquired a 44.4% stake in Hugel in 2017 for about 927.5 billion won. Bain’s holding in the botox maker is estimated to be worth about 2 trillion won including a control premium. (Reporting by Ha-na Suh)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- 우리금융 "롯데손보 M&A, 과도한 가격 부담 안한다"
- 신한캐피탈, 지속성장 포트폴리오 리밸런싱 체계 강화
- 하나금융, ELS 악재에도 실적 선방…확고한 수익 기반
- 하나금융, 자본비율 하락에도 주주환원 강화 의지
- 국민연금, '역대 최대 1.5조' 출자사업 닻 올렸다
- [도전 직면한 하이브 멀티레이블]하이브, 강한 자율성 보장 '양날의 검' 됐나
- [퍼포먼스&스톡]꺾여버린 기세에…포스코홀딩스, '자사주 소각' 카드 재소환
- [퍼포먼스&스톡]LG엔솔 예견된 실적·주가 하락, 비용 절감 '집중'
- [퍼포먼스&스톡]포스코인터, 컨센서스 웃돌았지만 주가는 '주춤'
- 신한금융, ‘리딩금융’ 재탈환에 주주환원 강화 자신감